Search | Clinical Trials Finder

Conditions: Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 30 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more

Conditions: Hepatic Impairment
Interventions: Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Saint Paul, Minnesota • San Antonio, Texas

Conditions: Glioblastoma
Interventions: Depatuxizumab mafodotin, Temozolomide, Lomustine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Up to 99 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Palo Alto, California • Aurora, Colorado • Denver, Colorado + 9 more

Conditions: Warts
Interventions: Resiquimod; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Jonesboro, Arkansas • San Francisco, California • Longmont, Colorado + 7 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions: FlorenceM (US) and FlorenceX (UK), Insulin pump therapy; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 6 Years to 18 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Hartford, Connecticut + 2 more

Conditions: ADHD, Autism, Bipolar I Disorder, Conduct Disorder, Oppositional Defiant Disorder
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more

Conditions: Measles; Mumps; Rubella; Chickenpox, Measles
Interventions: Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more

Conditions: CMV, AdV Infection, AdV Reactivation, Adenovirus, Cytomegalovirus Infections
Interventions: Standard of Care Antiviral medications, Viral CTLs; Drug · Biological
Lead sponsor: New York Medical College; Other
Eligibility: 1 Day to 30 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Valhalla, New York • Milwaukee, Wisconsin

Conditions: Vasculitis
Interventions: Avacopan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Minneapolis, Minnesota + 7 more

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: TAK-755, Standard of care; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 0 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more

Conditions: Sickle Cell Disease
Interventions: PCV21, 20vPCV; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more

Conditions: Diabetic Ketoacidosis
Interventions: Normal saline, Lactated Ringers; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: Up to 18 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
Interventions: SMOFlipid® (lipid injectable emulsion); Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Up to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pain, Acute
Interventions: Ibuprofen, Acetaminophen, Placebo; Drug
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 3 Years to 20 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Complicated Intra-abdominal Infections
Interventions: Ceftazidime -avibactam, Meropenem, Metronidazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Orange, California • San Diego, California • Toledo, Ohio + 1 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Gainesville, Florida • Pensacola, Florida • Atlanta, Georgia + 2 more

Conditions: Stress, Anesthesia, Children, Only, Anxiety, MRI, Sedation
Interventions: LEGO Bricks MRI, Mock MRI tube; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 4 Years to 10 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Infections, Respiratory Syncytial Virus
Interventions: Danirixin, CXCL1; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 64 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Chronic Diseases in Children
Interventions: Comprehensive care (CC) program, Enhanced telemedicine (ETM); Other · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 18 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cerebral Palsy
Interventions: commercial blenderized tube feed (CBTF), commercial formulas (CF); Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 3 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Surgical Bleeding
Interventions: Raplixa, Gelfoam, Rescue treatment; Drug · Device
Lead sponsor: Mallinckrodt; Industry
Eligibility: Up to 17 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 10 more

Conditions: Type 1 Diabetes Mellitus, Diet Modification, Child, Only
Interventions: Low carbohydrate diet, Very low carbohydrate diet; Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 2 Years to 11 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type 1 Diabetes, Children, Only
Interventions: telehealth visits; Other
Lead sponsor: Georgetown University; Other
Eligibility: 11 Years to 18 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Day and Night Closed-loop in Young People With Type 1 Diabetes

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

Double Blinded Randomized Control Trial of Types of IVF in Children With DKA

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

LEGO MRI: Decreasing the Need for Sedation, and Improving Patient Anxiety.

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

An Enhanced Home-Based Telemedicine Program Using Remote Examination Devices for Children With Medical Complexity

The Impact of Commercial Blenderized Formula on Caloric Needs, Gastrointestinal Symptoms, and Gut Microbiome in Children With Cerebral Palsy (CP)

Topical Raplixa for Surgical Bleeding in Children

Safety of Low and Very Low Carbohydrate Diets in Young Children With Type 1 Diabetes

Pediatric Boot Camp Program